ClinicalTrials.gg
CompletedNCT00929864Updated Feb 4, 2014Results posted

Abatacept Versus Adalimumab Head-to-Head

A Phase 3 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 84 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-04.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
869
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
7th of 63
869 · median 119
Started
2009
the only one that year
Phase 3
26 of 63
2 open now
Registered
22nd of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 7th largest by enrollment, is the only one that started in 2009, is one of 26 in phase 3, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria
  • Methotrexate failure
  • Naive to RA biologics
  • ≤5 years duration of disease
  • Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2
  • Willingness to self-inject subcutaneous (SC) drug

Exclusion criteria

Exclusion Criteria:

  • Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents
  • History of active or chronic hepatitis
  • Cancer in the last 5 years
  • History of severe chronic or recurrent bacterial or viral infections
  • Risk of tuberculosis
  • Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
869 participants (actual)

Study arms

  • Active comparator
    Abatacept

    Drug: Abatacept

  • Active comparator
    Adalimumab

    Drug: Adalimumab

Interventions

  • Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)

    Also known as: Orencia, BMS-188667

  • Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)

    Also known as: Humira

06

What researchers measure

Primary outcomes

  1. The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population

    Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have \>=20% fewer tender joints and \>=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation). Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.

    Time frame: Day 1 to Day 365

Secondary outcomes

  1. Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population

    n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk. Proportion (%) = n/N. 12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.

    Time frame: Day 1 to 12 Months

  2. Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population

    Incidence Rate: (incidence/100 person-years) = number of participants with event \* 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25. The 24 Month Period includes data up to 56 days post the last dose in the 24 month period. Poisson distribution used to construct the 95% CIs.

    Time frame: Day 1 to Day 729

  3. Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population

    Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729. BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign). SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films. Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (\<=) SDC(2.2). Proportion n/m (%)=number meeting criteria (n); number analyzed (m). SDC calculated as SD/sqrt(2)\*1.96/sqrt(2)with standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt). mSvdHS=summary of erosion severity in 32 hand and 12 foot joints. Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity. BL: radiographic data within 14 days or less of first dose.

    Time frame: Baseline to Day 729

  4. Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population

    Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Day 1 to Day 365

  5. Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population

    Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Day 1 to Day 729

  6. Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population

    The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729). Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline. Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.

    Time frame: Day 1 to Day 729

07

Results

Posted Jan 3, 2014

Participant flow

28-October-2009 to 23-November-2012. Study conducted in biologic-naive participants with Rheumatoid Arthritis (RA) who have failed on methotrexate therapy.

Participant flow — Overall Study
Milestone125 mg Abatacept SC Weekly40 mg Adalimumab SC Biweekly
Started318328
Completed252245
Not completed6683
Withdrew: Death11
Withdrew: Adverse event1130
Withdrew: Lack of efficacy1916
Withdrew: Lost to follow-up712
Withdrew: Withdrawal by subject209
Withdrew: No longer met criteria21
Withdrew: Poor or non-compliance33
Withdrew: Pregnancy03
Withdrew: Administrative reason by sponsor11
Withdrew: Non-specified27

Outcome measures

PrimaryThe Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population

Proportion(%)=number of participants meeting criteria (n) divided by number of participants who received drug (N). The ACR score indicates degree of improvement in a patient's rheumatoid arthritis (RA), based on guidelines set forth by the ACR and represents a percentage. To qualify a ACR20 score, patient must have \>=20% fewer tender joints and \>=20% fewer swollen joints and show 20% improvement from baseline in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein (CRP) test (to assess inflammation). Baseline was Day 1. Randomization was stratified using screening Disease Activity Score-28 (DAS28) CRP, a composite of 4 variables: number of tender joints/28, number of swollen joints/28, CRP in mg/L and participant assessment of disease activity with visual analogue scale.

Time frame:
Day 1 to Day 365
Reported as:
Number · percentage of participants
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population
percentage of participantsAbataceptAdalimumab
The Proportion of Participants Meeting the American College of Rheumatology (ACR) Criteria of 20% Improvement (ACR20) After 12 Months of Treatment - Intent to Treat Population64.8 (59.5 to 70.0)63.4 (58.2 to 68.6)
Statistical analysis
  • Abatacept vs Adalimumab · minimum risk weights method · Difference from adalimumab at day 365: 1.8 · 95% CI -5.6 to 9.2adjusted for randomization stratification of screening Disease Activity Score-28 (DAS28) c-reactive protein (CRP).
SecondaryProportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population

n=number of participants with a pre-specified local injection site reaction event, N=number of participants at risk. Proportion (%) = n/N. 12 Months includes data up to 56 days post last dose of the first 12 months Period or start of the first dose of second 12 months period.

Time frame:
Day 1 to 12 Months
Reported as:
Number · percentage of participants
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population
percentage of participantsAbataceptAdalimumab
Proportion of Participants With Local Injection Site Reactions Adverse Events (Pre-specified) Reported During 12 Month Period - ITT Population3.8 (1.68 to 5.87)9.1 (6.03 to 12.27)
Statistical analysis
  • Abatacept vs Adalimumab · Chi-squared · p = 0.006 · Difference in proportions: -5.37 · 95% CI -9.13 to -1.62
SecondaryIncidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population

Incidence Rate: (incidence/100 person-years) = number of participants with event \* 100 /exposure (person-years) Exposure (person-years) = the sum over all participants of the exposure per participant in the 24 months (censored at the time of first occurrence of AE) expressed in days, divided by 365.25. The 24 Month Period includes data up to 56 days post the last dose in the 24 month period. Poisson distribution used to construct the 95% CIs.

Time frame:
Day 1 to Day 729
Reported as:
Number · incidence/100 person years
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population
incidence/100 person yearsAbataceptAdalimumab
Incidence Rate of Local Injection Site Reactions (Pre-specified) Reported During 24 Month Period - ITT Population2.24 (1.20 to 3.84)6.38 (4.42 to 8.91)
Statistical analysis
  • Abatacept vs Adalimumab · Difference from adalimumab: -4.13 · 95% CI -6.55 to -1.72
SecondaryProportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population

Plain radiographs of hands and feet taken at baseline (BL), Day 365, and Day 729. BL and Day 365 radiographs were re-read concurrent with Day 729 films by readers blinded to sequence and treatment (a second pre-specified reading campaign). SDC defined as amount of change for which anything smaller could not be reliably distinguished from random error in measurement of simultaneously read films. Non-progression defined: change from BL (Day 1, prior to dosing) in total score less than, equal to (\<=) SDC(2.2). Proportion n/m (%)=number meeting criteria (n); number analyzed (m). SDC calculated as SD/sqrt(2)\*1.96/sqrt(2)with standard deviation (SD) of paired differences of change from BL in total score between 2 readers; squared root(sqrt). mSvdHS=summary of erosion severity in 32 hand and 12 foot joints. Hand joints scored 0 to 5; foot joints 0 to 10 with 0=no erosion and higher numbers indicating greater erosion severity. BL: radiographic data within 14 days or less of first dose.

Time frame:
Baseline to Day 729
Reported as:
Number · percentage of participants
Proportion of Participants Without Radiographic Progression in Total Score Less Than or Equal to the Smallest Detectable Change (SDC) From Baseline to Months 12 and 24 Using Modified Van Der Heijde Total Sharp Score (mSvdHS) - ITT Population
percentage of participantsAbataceptAdalimumab
Day 365 n=259, 263; m=295, 29787.8 (84.1 to 91.5)88.6 (84.9 to 92.2)
Day 729 n=218, 218; m=257, 26084.8 (80.4 to 89.2)83.8 (79.4 to 88.3)
Statistical analysis
  • Abatacept vs Adalimumab · minimum risk weights method · Difference from adalimumab at day 365: -1.3 · 95% CI -6.5 to 3.9Adjusted for randomization stratification of screening Disease Activity Score-28 (DAS28) c-reactive protein (CRP).
  • Abatacept vs Adalimumab · minimum risk weights method · Difference from adalimumab at day 729: 0.9 · 95% CI -5.5 to 7.3Adjusted for randomization stratification of screening Disease Activity Score-28 (DAS28) c-reactive protein (CRP).
SecondaryIncidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population

Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post-last dose of first 12 months or start of first dose of second 12 months); denominator was overall total exposure (person-years) within this period, calculated as sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Day 1 to Day 365
Reported as:
Number · incidence/100 person-years
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 12 Months of Treatment - ITT Population
incidence/100 person-yearsAbataceptAdalimumab
SAE (number with event=32, 30)11.06 (7.57 to 15.62)10.26 (6.92 to 14.65)
Serious Infections (number with event=7, 9)2.32 (0.93 to 4.79)2.99 (1.37 to 5.68)
Opportunistic infections (number with event=1, 1)0.33 (0.01 to 1.83)0.33 (0.01 to 1.85)
Discontinuation (number with event=44, 59)14.79 (10.74 to 19.85)20.11 (15.31 to 25.94)
Statistical analysis
  • Abatacept vs Adalimumab · Difference from adalimumab: 0.80 · 95% CI -4.51 to 6.11
  • Abatacept vs Adalimumab · Difference from adalimumab: -0.67 · 95% CI -3.27 to 1.94
  • Abatacept vs Adalimumab · Difference from adalimumab: -0.00 · 95% CI -0.92 to 0.91
  • Abatacept vs Adalimumab · Difference from adalimumab: -5.32 · 95% CI -12.06 to 1.41
SecondaryIncidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population

Pre-specified opportunistic infections include: pneumonia, tuberculosis, herpes zoster, combined opportunistic infections, and all hospitalized infections. Incidence Rate: incidence/100 person-years: numerator was number of unique events within this period (up to 56 days post the last dose of the 24 Months period); denominator was overall total exposure (person-years) within this period, which was calculated as the sum over all participants of exposure (in days) divided by 365.25. The resulting incidence rate was multiplied by 100 to express the rate per 100 person-years. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Day 1 to Day 729
Reported as:
Number · incidence/100 person-years
Incidence Rate of Serious Adverse Events (SAEs), Serious Infections, Pre-specified Opportunistic Infections, and Discontinuation for Any Cause at 24 Months of Treatment - ITT Population
incidence/100 person-yearsAbataceptAdalimumab
SAE Incidence Rate (number with event=44, 54)13.8 (10.04 to 17.63)16.5 (12.45 to 20.48)
Serious Infections (number with event=12, 19)3.8 (1.68 to 5.87)5.8 (3.26 to 8.32)
Opportunistic infections (number with event=2, 5)0.6 (0.00 to 1.50)1.5 (0.20 to 2.85)
Discontinuation (number with event=66, 83)20.8 (16.30 to 25.21)25.3 (20.60 to 30.01)
Statistical analysis
  • Abatacept vs Adalimumab · Difference from adalimumab: -1.91 · 95% CI -5.43 to 1.61
  • Abatacept vs Adalimumab · Difference from adalimumab: -1.24 · 95% CI -3.12 to 0.63
  • Abatacept vs Adalimumab · minimum risk weights method · Difference from adalimumab: -0.52 · 95% CI -1.39 to 0.36
  • Abatacept vs Adalimumab · Difference from adalimumab: -3.10 · 95% CI -7.13 to 0.92
SecondaryProportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population

The induction of autoantibodies was defined as participant's antinuclear antibodies (ANA) or anti-double stranded deoxyribonucleic acid (dsDNA) converting from a negative status at baseline to a positive status at a post-baseline measurement time point (Day 365 or Day 729). Proportion (%) = n/m, where n=number of participants with positive ANA or dsDNA at a time point and m=number of participants who had negative ANA or dsDNA at baseline. Blood samples were first tested for ANA by indirect fluorescent assay using HEp-2 Cell Line Substrate, and when positive, samples were further tested for anti-dsDNA by indirect fluorescent assay using Crithidia Luciliae Substrate.

Time frame:
Day 1 to Day 729
Reported as:
Number · Percentage of participants
Proportion of Participants With Induction of Autoantibodies During the 12 Months and 24 Months Periods - ITT Population
Percentage of participantsAbataceptAdalimumab
Day 365 ANA; n=12, 28; m=229, 2105.2 (2.4 to 8.1)13.3 (8.7 to 17.9)
Day 365 anti-dsDNA; n=1, 29; m=299, 2930.3 (0.0 to 1.0)9.9 (6.5 to 13.3)
Day 729 ANA; n=12, 24; m=190, 1636.3 (2.9 to 9.8)14.7 (9.3 to 20.2)
Day 729 anti-dsDNA; n=0, 29; m=248, 2370.0 (0.0 to 0.0)12.2 (8.1 to 16.4)
Statistical analysis
  • Abatacept vs Adalimumab · Difference from adalimumab: -8.1 · 95% CI -13.9 to -2.2
  • Abatacept vs Adalimumab · Difference from adalimumab: -8.4 · 95% CI -15.3 to -1.5
  • Abatacept vs Adalimumab · Difference from adalimumab: -9.6 · 95% CI -13.4 to -5.7
  • Abatacept vs Adalimumab · Difference from adalimumab: -12.2 · 95% CI -16.9 to -7.6

Adverse events

Collected over Includes data up to 56 days post the last dose in the 24 months period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept—43/318 (13.5%)237/318 (74.5%)
Adalimumab—54/328 (16.5%)232/328 (70.7%)
Most frequent serious events
Showing 10 of 108
Most frequent serious events
EventAbataceptAdalimumab
PneumoniaInfections and infestations3/3184/328
Cholecystitis acuteHepatobiliary disorders3/3180/328
Urinary tract infectionInfections and infestations3/3180/328
Non-cardiac chest painGeneral disorders1/3183/328
Arthritis bacterialInfections and infestations0/3183/328
CholelithiasisHepatobiliary disorders2/3181/328
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3180/328
Chest painGeneral disorders2/3180/328
Angina pectorisCardiac disorders2/3181/328
Rotator cuff syndromeMusculoskeletal and connective tissue disorders2/3180/328
Most frequent other events
Showing 10 of 20
Most frequent other events
EventAbataceptAdalimumab
Upper respiratory tract infectionInfections and infestations64/31855/328
NasopharyngitisInfections and infestations61/31857/328
SinusitisInfections and infestations51/31837/328
BronchitisInfections and infestations49/31843/328
Urinary tract infectionInfections and infestations41/31832/328
Back painMusculoskeletal and connective tissue disorders39/31839/328
HeadacheNervous system disorders32/31838/328
DiarrhoeaGastrointestinal disorders29/31823/328
NauseaGastrointestinal disorders26/31828/328
RashSkin and subcutaneous tissue disorders13/31827/328

Baseline characteristics

All randomized and treated participants who started the 12 month period.

Age, Continuous
Age, Continuous(years)AbataceptAdalimumabTotal
Mean51.4 ± 12.651.0 ± 12.851.2 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptAdalimumabTotal
Female259270529
Male5958117
Region of Enrollment
Region of Enrollment(participants)AbataceptAdalimumabTotal
North America230235465
South America8893181
08

Study locations

84 sites
  • Rheumatology Associates, Pc
    Birmingham, Alabama 35205, United States
  • University Of Alabama At Birmingham
    Birmingham, Alabama 35294, United States
  • Clinical And Translational Research Center Of Alabama, Pc
    Tuscaloosa, Alabama 35406, United States
  • Sun Valley Arthritis Center, Ltd.
    Peoria, Arizona 85381, United States
  • Mercy Clinic Hot Springs Communities
    Hot Springs, Arkansas 71913, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • Allergy & Rheumatology Medical Clinic, Inc.
    La Jolla, California 92037, United States
  • Valerius Med Group & Res Ctr Of Greater Long Beach, Inc.
    Long Beach, California 90806, United States
  • Irene Y. Tong
    Pasadena, California 91107, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Healthcare Partners Medical Group
    Torrance, California 90503, United States
  • Drs. Goldin, Nies, Klashman & Eng
    Torrance, California 90505, United States
  • Inland Rheumatology & Osteoporosis Medical Group
    Upland, California 91786, United States
  • Arthritis And Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • University Of Florida College Of Medicine At Jacksonville
    Gainesville, Florida 32610, United States
  • Center For Arthritis And Rheumatic Diseases
    Miami, Florida 33173, United States
  • Arthritis Research Of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Sarasota Arthritis Research Center
    Sarasota, Florida 34239, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • West Broward Rheumatology Associates
    Tamarac, Florida 33321, United States
  • Lovelace Scientific Resources, Inc
    Venice, Florida 34292, United States
  • Arthritis & Rheumatology Of Georgia
    Atlanta, Georgia 30342, United States
  • Laureate Clinical Research Group
    Atlanta, Georgia 30342, United States
  • Arthritis Center Of North Georgia
    Gainesville, Georgia 30501, United States
  • St. Luke'S Clinic - Rheumatology
    Boise, Idaho 83702, United States
  • Coeur D'Alene Arthrit Clin
    Coeur D Alene, Idaho 83814, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Rockford Orthopedic Associates, Ltd.
    Rockford, Illinois 61107, United States
  • Physicians Clinic Of Iowa
    Cedar Rapids, Iowa 52401, United States
  • Center For Arthritis And Osteoporosis
    Elizabethtown, Kentucky 42701, United States
  • Bluegrass Community Research, Inc.
    Lexington, Kentucky 40504, United States
  • Klein And Associates, M.D., Pa
    Cumberland, Maryland 21502, United States
  • The Center For Rheumatology And Bone Research
    Wheaton, Maryland 20902, United States
  • Brigham And Women'S Hospital
    Boston, Massachusetts 02115, United States
  • Mansfield Health Center
    Mansfield, Massachusetts 02048, United States
  • Associated Internal Medicine Specialists
    Battle Creek, Michigan 49015, United States
  • Rheumatology Pc
    Kalamazoo, Michigan 49009, United States
  • Arthritis Associates Of Mississippi
    Jackson, Mississippi 39202, United States
  • Physician Groups, Lc Dba
    St.Louis, Missouri 63131, United States
  • Arthritis Center Of Reno
    Reno, Nevada 89502, United States
  • Seacoast Arthritis And Osteoporosis Center
    Dover, New Hampshire 03820, United States
  • Nashua Rheumatology
    Nashua, New Hampshire 03060, United States
  • Arthritis And Osteoporosis Associates Of New Mexico
    Las Cruces, New Mexico 88011, United States
  • North Shore Lij Health System
    Lake Success, New York 11042, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Rheumatology Associates Of Long Island
    Smithtown, New York 11787, United States
  • Asheville Rheumatology & Osteoporosis Research Asso P. A.
    Asheville, North Carolina 28803, United States
  • Carolina Pharmaceutical Research
    Statesville, North Carolina 28625, United States
  • Health Research Of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73109, United States
  • Lynn Health Sciences Institute
    Oklahoma City, Oklahoma 73112, United States
  • East Penn Rheumatology Associates, P.C.
    Bethlehem, Pennsylvania 18015, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center Of Reading, Llp
    Wyomissing, Pennsylvania 19610, United States
  • Low Country Rheumatology, Pa
    Charleston, South Carolina 29406, United States
  • Columbia Arthritis Center, P.A.
    Columbia, South Carolina 29204, United States
  • Lovelace Scientific Resources, Inc.
    Austin, Texas 78758, United States
  • Arthritis Centers Of Texas
    Dallas, Texas 75246, United States
  • Rheumatic Disease Clinical Research Center, Llc
    Houston, Texas 77004, United States
  • Center For Arthritis & Rheumatic Diseases, Pc
    Chesapeake, Virginia 23320, United States
  • Rockwood Research Center
    Spokane, Washington 99202, United States
  • Mountain State Clinical Research
    Clarksburg, West Virginia 26301, United States
  • Rheumatic Disease Center
    Glendale, Wisconsin 53217, United States
  • Local Institution
    Ciudad Autonoma De Beunos Aire, Buenos Aires 1431, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires 1015, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires C1428DQG, Argentina
  • Local Institution
    Ciudad Autonoma, Buenos Aires CP1425A WC, Argentina
  • Local Institution
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution
    Cordoba, Crd, Cordoba X5016KEH, Argentina
  • Local Institution
    Rosario, Santa Fe 2000, Argentina
  • Local Institution
    San Miguel De Tucuman, Tucuman 4000, Argentina
  • Local Institution
    Cordoba, 5000, Argentina
  • Local Institution
    San Juan, 5400, Argentina
  • Local Institution
    Tucuman, 4000, Argentina
  • Local Institution
    Winnipeg, Manitoba R3A 1M3, Canada
  • Local Institution
    Hamilton, Ontario L8N 1Y2, Canada
  • Local Institution
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Local Institution
    Quebec, G1V 3M7, Canada
  • Local Institution
    Santiago, Providencia, Chile
  • Local Institution
    Bellavista, Callao 2, Peru
  • Local Institution
    Lima, LIMA 11, Peru
  • Local Institution
    Lima, LIMA 27, Peru
  • Local Institution
    Lima, LIMA 33, Peru
  • Local Institution
    Lima, Peru
09

References and documents

Publications

  • Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE. Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatol Ther. 2022 Apr;9(2):391-409. doi: 10.1007/s40744-021-00404-x. Epub 2021 Dec 8. PubMed 34878629 ↗
  • Keystone EC, Ahmad HA, Yazici Y, Bergman MJ. Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. Rheumatology (Oxford). 2020 Aug 1;59(8):2090-2098. doi: 10.1093/rheumatology/kez455. PubMed 31819995 ↗
  • Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M. Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019 Dec;6(4):559-571. doi: 10.1007/s40744-019-00174-7. Epub 2019 Oct 22. PubMed 31642045 ↗
  • Fleischmann R, Connolly SE, Maldonado MA, Schiff M. Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. Arthritis Rheumatol. 2016 Sep;68(9):2083-9. doi: 10.1002/art.39714. PubMed 27111089 ↗
  • Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R. Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open. 2016 Apr 19;2(1):e000210. doi: 10.1136/rmdopen-2015-000210. eCollection 2016. PubMed 27110385 ↗
  • Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE. Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 Jul;68(7):907-13. doi: 10.1002/acr.22763. PubMed 26473625 ↗
  • Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr;75(4):709-14. doi: 10.1136/annrheumdis-2015-207942. Epub 2015 Sep 10. PubMed 26359449 ↗
  • Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan;73(1):86-94. doi: 10.1136/annrheumdis-2013-203843. Epub 2013 Aug 20. PubMed 23962455 ↗
  • Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711. PubMed 23169319 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Oct 2011 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2009
First posted
Jun 30, 2009
Start
Oct 2009
Primary completionActual
Oct 2011
CompletionActual
Nov 2012
Results first posted
Jan 3, 2014
Last update
Feb 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00929864
Responsible party
Sponsor
First posted
Jun 30, 2009
Start date
Oct 2009
Primary completion
Oct 2011
Completion
Nov 2012
Results posted
Jan 3, 2014
Last update
Feb 4, 2014

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abatacept · Adalimumab

Start the discussion